NasdaqGS:APLSBiotechs
Apellis Pharmaceuticals (APLS) Is Up 11.2% After FDA Approves EMPAVELI for Rare Kidney Diseases
Apellis Pharmaceuticals recently received U.S. FDA approval for EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years and older, based on positive Phase 3 study results showing significant disease improvement.
This approval addresses a critical unmet need for rare kidney diseases affecting about 5,000 people in the U.S., potentially expanding Apellis’s reach in a new...